CA
NZ
UK
AU
IND
US
MapLight Therapeutics posted an earnings per share of -1.34 for the quarter, missing the -1.12 consensus forecast. The miss coincided with the company's presentation of top-line results from its recent trial in schizophrenia, which offered mixed signals on efficacy. Despite the earnings disappointment, the …
The latest clinical data from ORYZON Genomics highlights significant advancements in cancer treatment, particularly for acute myeloid leukemia (AML). The company reported a remarkable 100% overall response rate (ORR) for its leading drug, iadademstat, when used in conjunction with azacitidine and venetoclax. Such compelling …
ProMIS Neurosciences Inc. has reported an adjusted earnings per share of $-1.26 for the quarter ending March 31, 2026, significantly better than the anticipated consensus estimate of $-1.49. This positive variance has fueled enthusiasm among investors.
Aptevo Therapeutics Inc. (NASDAQ: APVO) has secured a provisional patent covering a Nectin‑4 × PD‑L1 dual‑targeting backbone, broadening its solid‑tumor portfolio beyond a single investigational product. The filing protects a core molecular architecture that can be adapted for a range of therapeutic formats, including …
Camp4 Therapeutics Corp (NASDAQ: CAMP) has secured a significant funding opportunity after receiving regulatory clearance for its clinical trial. This development is a notable milestone for the company, as it progresses in its efforts to develop innovative treatments for genetic diseases. The clearance paves …
Rudy Irvin Robert, a director at First United Corp/Md/ (NASDAQ: FUNC), disclosed a sale of 1,000 common shares on July 24, 2026, at a price of $44.58 per share, according to a regulatory filing released July 28, 2026. Following the transaction, Robert's direct beneficial …
Scotts Miracle-Gro Company disclosed that Mark J. Scheiwer, Executive Vice President, Chief Financial Officer, and Chief Administrative Officer, acquired 3.911 shares of phantom stock on July 27, 2026. The transaction, reported in a regulatory filing dated July 28, 2026, reflects ongoing equity-based compensation arrangements …
Bristol Myers Squibb (NYSE: BMY) has drawn notable attention as Izzy Englander, a prominent hedge fund manager with a net worth nearing $25.8 billion, significantly increased his stake in the company by a staggering 780% during the first quarter of 2026. This substantial repositioning …
Cosmos Health Inc. has unveiled a subscription platform customized for health products, marking a significant step in enhancing its service offerings. This strategic initiative aims to cater to a growing consumer demand for convenient access to healthcare solutions. However, the announcement comes at a …
Textron Inc. disclosed second quarter 2026 financial results in its quarterly earnings report filed with the Securities and Exchange Commission on July 28, 2026. The disclosure provides detailed segment performance across the company's Manufacturing and Finance groups, along with operational metrics covering product and …
Please wait processing your request...